pre-IPO PHARMA
COMPANIES
VC
JOBS
NEWS
CONTACT
Close ×
COMPANIES
VC
JOBS
NEWS
CONTACT
COMPANY OVERVIEW
Innocrin is a privately held, clinical-stage pharmaceutical company that discovers and develops novel, best-in-class oral selective inhibitors of CYP17 lyase, a validated target for the treatment of advanced breast and prostate cancer.
LOCATION
THERAPEUTIC AREAS
Oncology
WEBSITE
https://innocrinpharma.com
CAREER WEBSITE
https://innocrinpharma.org/contact-us/careers/
SOCIAL MEDIA
INVESTORS
PRESS RELEASES
Jun 20, 2017
Innocrin Pharmaceuticals, Inc. Granted SME Status Designation by the European Medicines Agency
Apr 6, 2017
Innocrin Pharmaceuticals Appoints Fred Eshelman, PharmD as CEO and is Granted Fast Track Designation by FDA for Seviteronel Treatment of Women with Triple-negative Breast Cancer and Women or Men with Estrogen Receptor-positive Breast Cancer
Dec 13, 2016
Innocrin Pharmaceuticals Presents Data from the Ongoing Phase 2 Trial of Seviteronel in Estrogen Receptor-positive or Triple-negative Breast Cancer (CLARITY-01) at the San Antonio Breast Cancer Symposium
Oct 5, 2016
Innocrin Pharmaceuticals, Inc. Appoints Edwina Baskin-Bey, MD as Chief Medical Officer and Expands the Ongoing Phase 2 Study of Seviteronel in Women with Estrogen Receptor-positive or Triple-negative Breast Cancer (TNBC)
May 12, 2016
Innocrin Pharmaceuticals, Inc. Begins Phase 2 Study of Seviteronel in Women with Estrogen Receptor-positive or Triple-negative Breast Cancer and Expands Two Phase 2 Studies of Seviteronel in Men with Metastatic Castrate-resistant Prostate Cancer
For More Press Releases